Crossmark

Separation and Characterization of New Forced Degradation Products of Dasatinib in Tablet Dosage Formulation Using LC–MS and Stability-Indicating HPLC Methods

Crossref DOI link: https://doi.org/10.1007/s10337-020-03920-0

Published Online: 2020-06-15

Published Print: 2020-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lakka, Narasimha S.

Kuppan, Chandrasekar https://orcid.org/0000-0002-3780-6222
Srinivas, Kona S.

Yarra, Raviteja
License Information

Text and Data Mining valid from 2020-06-15

Version of Record valid from 2020-06-15
More Information

Article History

Received: 5 December 2019

Revised: 1 June 2020

Accepted: 8 June 2020

First Online: 15 June 2020

Compliance with Ethical Standards

:

: The authors declare no conflict of interest.

Document is current

Any future updates will be listed below